U.S. stock futures traded around the flatline Thursday ahead of the release of key economic data, which could provide clues over future Federal Reserve monetary policy.
Here are some of the biggest premarket U.S. stock movers today:
Intel (NASDAQ:INTC) stock gained 1.9%, continuing the previous session’s upside after Bloomberg News reported that the chipmaker approached tech giant Apple about securing an investment.
- International Business Machines (NYSE:IBM) stock rose 3.3% after HSBC (LON:HSBA) announced it had successfully completed the world’s first-known quantum-enabled algorithmic trading trial using IBM’s quantum computing technology.
Accenture (NYSE:ACN) stock rose 0.2% after the professional services company reported fourth-quarter revenue slightly above expectations, driven by resilient demand for its artificial intelligence-driven consulting and services from enterprise clients.
Starbucks (NASDAQ:SBUX) stock rose 0.2% after the coffee giant approved a restructuring plan involving the closure of underperforming coffee houses as the company looks to revive sales and profits under CEO Brian Niccol.
CarMax (NYSE:KMX) stock slumped 11% after the used car retailer’s second-quarter earnings significantly missed expectations, with both revenue and profit declining amid challenging market conditions.
PepsiCo (NASDAQ:PEP) stock fell 0.2% after the soft drinks giant received a 30-day negative short-term view from Citigroup.
Lithium Americas (TSX:LAR) stock climbed 20%, after nearly doubling in the previous session, following a Reuters report that President Donald Trump’s administration is seeking an up to 10% stake in the miner.
Opendoor Technologies (NASDAQ:OPEN) stock rose 5% after trading firm Jane Street disclosed a 5.9% stake in the residential real estate platform.
Transocean (NYSE:RIG) stock slumped 15% after the offshore drilling contractor announced a public offering of 125 million shares, with the proceeds set to be used for debt repayment and general corporate purposes.
Immuneering Corp (NASDAQ:IMRX) stock jumped 22% after the biotech firm reported 86% overall survival at nine months in first-line pancreatic cancer patients treated with its atebimetinib drug in combination with mGnP, a chemotherapy regime.
